Managers / Q2 2023 · view latest →
HARBOURVEST PARTNERS LLC
CIK 0001201001 · ONE LINCOLN STREET, SUITE 1700, BOSTON, MA, 02111 · 617-348-3707
Reported Value
$352M
Q2 2023
Positions
60
Filings on Record
32
2019–present window
Filed
Aug 14, 2023
original filing
Summary
Harbourvest Partners LLC reported $352M in U.S.-listed holdings across 60 positions for Q2 2023.
Its largest position, W, represents 19.6% of the portfolio.
Compared with Q1 2023, the fund opened 4 new positions and exited 7.
Portfolio Metrics
Turnover
+6.9%
vs prior filed quarter
Top-10 Concentration
+80.6%
share of reported value
Largest Position
+19.6%
Wayfair
New / Exited
4 / 7
positions this quarter
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
13F Reported Value
Portfolio Composition
By security type
- Common Stock · 87.8% · $309M
- Other · 8.7% · $31M
- ADR · 3.5% · $12M
Quarter-over-Quarter Changes full breakdown →
vs Q1 2023 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| Sigilon Therapeutics, Inc. | NEW | +57.0K | 57.0K | +$1M | $1M |
| PLRXPliant Therapeutics, Inc. | NEW | +49.4K | 49.4K | +$895,744 | $895,744 |
| Bright Health Group, Inc. | NEW | +52.7K | 52.7K | +$644,238 | $644,238 |
| EVLOEvelo Biosciences, Inc. | NEW | +153.2K | 153.2K | +$497,819 | $497,819 |
| AFRMAffirm, Inc. | ADDED | +244.9K | 268.1K | +$4M | $4M |
| HOODRobinhood Markets Inc. | ADDED | +189.5K | 240.2K | +$2M | $2M |
| GTMZoom Information, Inc | ADDED | +77.8K | 116.5K | +$2M | $3M |
| PGNYProgyny, Inc. | ADDED | +57.8K | 89.7K | +$3M | $4M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q2 2023
60 positions
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | WWayfair Inc.history → | Common CLA | 19.61% | $69M | 1.06M |
| 2 | TOSTToast, Inc.history → | Common CLA | 14.63% | $52M | 2.28M |
| 3 | NABLN-Able, Inc.history → | Common | 13.92% | $49M | 3.40M |
| 4 | Solarwinds Corp. | Common | 10.84% | $38M | 3.72M |
| 5 | MNDYmonday.com Ltd.history → | SHS | 9.49% | $33M | 195.2K |
| 6 | Omega Therapeutics, Inc. | Common | 5.59% | $20M | 3.51M |
| 7 | HSAIHesai Grouphistory → | Sponsored ADS | 1.81% | $6M | 606.1K |
| 8 | YMMFull Truck Alliance Co. Ltd.history → | Sponsored ADS | 1.69% | $6M | 957.6K |
| 9 | HashiCorp, Inc. | Common CLA | 1.56% | $5M | 209.3K |
| 10 | Hammerhead Energy Inc. | Common CLA | 1.48% | $5M | 716.9K |
| 11 | LendingClub Corp. | Common | 1.42% | $5M | 513.4K |
| 12 | AFRMAffirm, Inc.history → | Common CLA | 1.17% | $4M | 268.1K |
| 13 | RLAYRelay Therapeutics, Inc.history → | Common | 1.06% | $4M | 296.4K |
| 14 | PGNYProgyny, Inc.history → | Common | 1.00% | $4M | 89.7K |
| 15 | GTMZoom Information, Inc | Common | 0.84% | $3M | 116.5K |
| 16 | Olo, Inc. | Common CLA | 0.79% | $3M | 431.3K |
| 17 | SPOTSpotify Technology S.A. | SHS | 0.76% | $3M | 16.8K |
| 18 | FTCHQFarfetch Ltd. | Ordinary Shares CLA | 0.76% | $3M | 442.7K |
| 19 | BEBloom Energy Corporation | Common CLA | 0.75% | $3M | 162.2K |
| 20 | ACVAACV Auctions, Inc. | Common CLA | 0.72% | $3M | 147.1K |
| 21 | HOODRobinhood Markets Inc. | Common CLA | 0.68% | $2M | 240.2K |
| 22 | Sonder Holdings, Inc. | Common CLA | 0.68% | $2M | 4.50M |
| 23 | COURCoursera, Inc. | Common | 0.64% | $2M | 172.2K |
| 24 | Inari Medical | Common | 0.64% | $2M | 38.5K |
| 25 | Zuora, Inc. | Common | 0.51% | $2M | 163.9K |
| 26 | DOCNDigital Ocean, Inc. | Common | 0.50% | $2M | 44.2K |
| 27 | IASIntegral Ad Science, Inc. | Common | 0.49% | $2M | 96.8K |
| 28 | DOCSDoximity, Inc. | Common CLA | 0.48% | $2M | 49.8K |
| 29 | AMPLAmplitude Inc. | Common CLA | 0.48% | $2M | 153.0K |
| 30 | PATHUiPath, Inc. | Common CLA | 0.48% | $2M | 101.4K |
| 31 | FROGJfrog Ltd. | ORD SHS | 0.46% | $2M | 59.0K |
| 32 | UUnity Software | Common | 0.42% | $1M | 34.2K |
| 33 | Axcella Health, Inc. | Common | 0.38% | $1M | 6.21M |
| 34 | Sigilon Therapeutics, Inc. | Common | 0.36% | $1M | 57.0K |
| 35 | Eventbrite, Inc. | Common CLA | 0.28% | $975,666 | 102.2K |
| 36 | IBRXImmunityBio, Inc. | Common | 0.27% | $933,271 | 335.7K |
| 37 | TWLOTwilio, Inc. | Common CLA | 0.26% | $927,071 | 14.6K |
| 38 | PLRXPliant Therapeutics, Inc. | Common | 0.25% | $895,744 | 49.4K |
| 39 | ONTFON24, Inc. | Common | 0.25% | $886,785 | 109.2K |
| 40 | HNSTThe Honest Company Inc. | Common | 0.23% | $799,057 | 475.6K |
| 41 | DIBS1stdibs.com, Inc. | Common | 0.21% | $746,115 | 199.5K |
| 42 | Bright Health Group, Inc. | Common | 0.18% | $644,238 | 52.7K |
| 43 | PINSPinterest, Inc. | Common CLA | 0.17% | $582,615 | 21.3K |
| 44 | EVLOEvelo Biosciences, Inc. | Common | 0.14% | $497,819 | 153.2K |
| 45 | CPNGCoupang Inc. | Common CLA | 0.13% | $466,912 | 26.8K |
| 46 | PACBPacific Biosciences of California, Inc. | Common | 0.09% | $312,337 | 23.5K |
| 47 | Seres Therapeutics, Inc. | Common | 0.07% | $236,449 | 49.4K |
| 48 | QSQuantumScape Corporation | Common CLA | 0.07% | $231,318 | 29.0K |
| 49 | DASHDoorDash, Inc. | Common CLA | 0.05% | $191,432 | 2.5K |
| 50 | OPENOpendoor Technologies Inc. | Common | 0.05% | $187,762 | 46.7K |
| 51 | RPTXRepare Therapeutics, Inc. | Common | 0.04% | $129,880 | 12.3K |
| 52 | Rallybio Holdings, LLC | Common | 0.04% | $123,824 | 21.9K |
| 53 | RYTMRhythm Pharmaceuticals, Inc. | Common | 0.03% | $92,987 | 5.6K |
| 54 | IPSCCentury Therapeutics, Inc. | Common | 0.03% | $91,697 | 29.0K |
| 55 | PMVPPMV Pharmaceuticals | Common | 0.02% | $72,197 | 11.5K |
| 56 | Astra Space, Inc. | Common CLA | 0.02% | $68,805 | 186.7K |
| 57 | Aligos Therapeutics, Inc. | Common | 0.01% | $18,238 | 18.8K |
| 58 | NextCure, Inc. | Common | 0.01% | $18,079 | 10.0K |
| 59 | Spark Networks SE | Sponsored ADR | 0.00% | $16,440 | 52.2K |
| 60 | GreenLight Biosciences, Inc. | Common | 0.00% | $14,558 | 48.8K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $101M | 5 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $174M | 7 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $205M | 9 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $91M | 15 | Aug 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $154M | 16 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $203M | 22 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $192M | 34 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $188M | 40 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $219M | 48 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $299M | 53 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $295M | 58 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $352M | 60 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $297M | 63 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $299M | 65 | Feb 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $306M | 67 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $305M | 62 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $490M | 66 | May 26, 2022 | RESTATEMENT | changes · EDGAR ↗ |
| Q4 2021 | $782M | 67 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $1.1B | 56 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $1.0B | 51 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $746M | 44 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $256M | 26 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $270M | 36 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $232M | 28 | Aug 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $207M | 36 | May 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $243M | 35 | Feb 13, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $240M | 33 | Nov 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $262M | 32 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $283M | 33 | May 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $211M | 32 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.